Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer

The frequent activation of the PI3K/AKT/mTOR pathway and its crucial role in estrogen receptor-positive (ER+) breast cancer tumorigenesis and drug resistance has made it a highly attractive therapeutic target in this breast cancer subtype. Consequently, the number of new inhibitors in clinical devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Carla L., Ditzel, Henrik J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003259/
https://www.ncbi.nlm.nih.gov/pubmed/36901954
http://dx.doi.org/10.3390/ijms24054522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003259/
https://www.ncbi.nlm.nih.gov/pubmed/36901954
http://dx.doi.org/10.3390/ijms24054522

Ejemplares similares